

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2009

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 30.09.2009 (Unaudited)	Quarter ended 30.09.2008 (Unaudited)	Nine Months ended 30.9.2009 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
1 (a) Net Sales	2,585	2,479	7,373	7,134	9,833
(b) Other Operating Income	190	137	585	367	532
Total	2,775	2,616	7,958	7,501	10,365
2 Expenditure					
a) Increase /decrease in stock in trade and work in progress	(178)	(96)	(387)	(33)	(104)
b) Consumption of raw materials	848	835	2,763	2,141	3,077
c) Purchase of traded goods	595	479	1,196	1,252	1,583
d) Employees Cost	380	291	1,058	868	1,192
e) Depreciation	44	43	129	138	182

Particulars	Quarter ended 30.09.2009 (Unaudited)	Quarter ended 30.09.2008 (Unaudited)	Nine Months ended 30.9.2009 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
f) Other expenditure	544	491	1,428	1,451	2,022
g) Total	2,233	2,043	6,187	5,883	8,160
3 Profit from Operations before Other Income and Interest (1-2)	542	573	1,771	1,618	2,205
4 Other Income	99	116	273	271	394
5 Profit before Interest (3+4)	641	689	2,044	1,889	2,599
6 Interest	-	-	-	1	3
7 Profit before tax (5-6)	641	689	2,044	1,888	2,596
8 Tax Expense	203	243	730	679	934
9 Net Profit for the Period (7-8)	438	446	1,314	1,209	1,662
10 Paid-up equity share capital (Face Value of Rs.10 per Share)	230	230	230	230	230
11 Reserves excluding Revaluation Reserves as per	-	-	-	-	7,881

Particulars	Quarter ended 30.09.2009 (Unaudited)	Quarter ended 30.09.2008 (Unaudited)	Nine Months ended 30.9.2009 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
balance sheet of previous accounting year					
12 Earnings Per Share (EPS) (Rs) (Basic and diluted EPS for the period for the year to date and for the previous year	19.04	19.39	57.13	52.56	72.16
13 Public Shareholding					
- Number of Shares	9,120,955	9,120,955	9,120,955	9,120,955	9,120 955
- Percentage of Shareholding	39.60	39.60	39.60	39.60	39.60
14 Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of Shares	2,365,920		2,365,920		
- Percentage of shares (as a % of	17.01%		17.01%		

Particulars	Quarter ended 30.09.2009 (Unaudited)	Quarter ended 30.09.2008 (Unaudited)	Nine Months ended 30.9.2009 (Unaudited)	Nine Months ended 30.9.2008 (Unaudited)	Year ended 31.12.2008 (Audited)
total shareholding of promoter and promoter group)					
- Percentage of shares (as a % of total share capital of the company)	10.27%		10.27%		
b) Non-encumbered					
- Number of Shares	11,543,747		11,543,747		
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	82.99%		82.99%		
- Percentage of shares (as a % of total share capital of the company)	50.13%		50.13%		

Notes:

- The above results were approved by the Board of Directors of the Company at its Meeting held on October 27, 2009.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the nine months ended September 30, 2009.

- The Company discontinued the distribution of the anti-rabies vaccine, Rabipur from February 19, 2009, pursuant to the Award of the Arbitrator in the matter relating to the disputes between the Company, Novartis Vaccines and Diagnostics Inc. and Chiron Behring Vaccines Private Limited (CBVPL) regarding the non-renewal of the Distribution Agreement for Rabipur. The Company continues to hold 49% of the share capital of CBVPL.
- The break up of Net Sales is as follows:

Rs Million

	Quarter ended Sept 30, 2009	Quarter ended Sept 30, 2008	Growth %	Nine Months ended Sept 30, 2009	Nine Months ended Sept 30, 2008	Growth %
Domestic Sales-Others	2,025	1,743	16.2%	5,534	4,836	14.4%
Domestic Sales-Rabipur	-	214	-100.0%	92	884	-89.6%
Export Sales	560	522	7.3%	1,747	1,414	23.6%
Total Sales	2,585	2,479	4.3%	7,373	7,134	3.4%

Excluding the impact of discontinuation of Rabipur distribution, comparable sales growth is 14.1% for the quarter and 16.5% for the nine months ended September 30, 2009.

- The Company has a single business segment namely 'Pharmaceutical Business'.
- The Board of Directors had declared an Interim Dividend of Rs. 3.50 per Equity share of Rs 10 for the year ending December 31, 2009. The dividend (including the Dividend Distribution Tax) amounted to Rs. 94.30 million. The said dividend was paid on August 12, 2009 through Electronic Clearing Service /Dividend Warrants.
- Information on investor complaints is furnished below:

Pending as on July 1, 2009	Received during the quarter	Disposed of during the quarter	Pending as on September 30, 2009

Pending as on July 1, 2009	Received during the quarter	Disposed of during the quarter	Pending as on September 30, 2009
Nil	5	5	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR